

Please amend the specification as follows:

Please replace pages 1-4 of the originally filed Sequence Listing with the enclosed substitute Sequence Listing.

Please replace the third full paragraph on page 20, lines 16-24 of the specification with the following amended paragraph:

Preferably, the isolated and recombinant fusion peptabody of the present invention further comprises an enhancer sequence. The enhancer sequence is selected from the group comprising: YSFE (SEQ ID NO: 5), YSFED (SEQ ID NO: 30), YSFEDL (SEQ ID NO: 6), YSFEDLY (SEQ ID NO: 7), YSFEDLYR (SEQ ID NO: 8) and YSFEDLYRR (SEQ ID NO: 9), a fragment thereof, a molecular chimera thereof and variants thereof. It has been shown that the presence of an enhancer sequence at the N terminus and preferably the above selected enhancers leads to a production rate which is 20 to 100 fold higher (see Fig. 25 and 26). However, one skilled in the art will be able to select other suitable enhancer sequences without departing from the scope of this invention.

Please replace Table 1, page 21, with the following amended Table 1:

Name		Sequence		Origin
Plasmocyte Spreading Peptide 1	Psi PSP1	ENFNGGCLAGYMRTADGRCKPTF (<u>SEQ ID NO:10</u>)	23 a.a.	<i>Pseudoplusia includens</i>
Sp1 Growth Blocking Peptide	Sp1 GBP	ENFSGGCVAGYMRTPDGRCKPTFYQ (<u>SEQ ID NO:11</u>)	25 a.a.	<i>Spodoptera litura</i>
Mab Growth Blocking Peptide	Mab GBP	ENFAAGCATGYQRTADGRCKPTF (<u>SEQ ID NO:12</u>)	23 a.a.	<i>Mamestra brassicae</i>
Spe Paralytic Peptide 1	Spe PP1	ENFAGGCATGYLRTADGRCKPTF (<u>SEQ ID NO:13</u>)	23 a.a.	<i>Spodoptera eridania</i>
Mas Paralytic Peptide 1	Mas PP1	ENFAGGCAAGYLRTADGRCKPTF (<u>SEQ ID NO:14</u>)	23 a.a.	<i>Manduca sexta</i>
Mas Paralytic Peptide 2	Mas PP2	ENFAGGCATGFLRTADGRCKPTF (<u>SEQ ID NO:15</u>)	23 a.a.	<i>Manduca sexta</i>
Hev Paralytic Peptide 1	Hev PP1	ENFSGGCI PGYMRTADGRCKPTY (<u>SEQ ID NO:16</u>)	23 a.a.	<i>Heliothis virescens</i>
Hev Paralytic Peptide 2	Hev PP2	ENFAGGCI PGYMRTADGRCKPTY	23 a.a.	<i>Heliothis virescens</i>

		<u>(SEQ ID NO:17)</u>		
Tm Paralytic Peptide 1	Tm PP1	ENFSGGCLAGYMRTADGRCKPTFG <u>(SEQ ID NO:18)</u>	24 a.a.	<i>Trichoplusia ni</i>
Tm Paralytic Peptide 2	Tm PP2	ENFSGGCLAGYMRTADGRCKPTF <u>(SEQ ID NO:19)</u>	23 a.a.	<i>Trichoplusia ni</i>
Any Paralytic Peptide	Any PP	ENFAGGCATGFMRTADGRCKPTF <u>(SEQ ID NO:20)</u>	23 a.a.	<i>Antheraea yamamai</i>
Spe Cardioactive Peptide	Spe CAP	ENFAVGCTPGYQRTADGRCKPTF <u>(SEQ ID NO:21)</u>	23 a.a.	<i>Spodoptera eridania</i>
Spe Paralytic Peptide 1	Spe PP1	ENFAGGCTPGYQRTADGRCKATF <u>(SEQ ID NO:22)</u>	23 a.a.	<i>Spodoptera eridania</i>
Spe Paralytic Peptide 2	Spe PP2	ENFAGGCTPGYQRTADGRCKPTF <u>(SEQ ID NO:23)</u>	23 a.a.	<i>Spodoptera eridania</i>
Spe Paralytic Peptide 3	Spe PP3	ENFVGCTPGYQRTADGRCKPTF <u>(SEQ ID NO:24)</u>	23 a.a.	<i>Spodoptera eridania</i>
Transforming Growth Factor α	TGF α	VVSHFNDPCDSHTQFCFHGTCRFLV QEDKPACVCHSGYVGARCEHADLLA <u>(SEQ ID NO:25)</u>	50a.a.	Human
Amphiregulin	AR	SVRVEQVVKPPQNKTESENTSDKPKRKKK GGKNGKNRRNRKKKNPCNAEFQNFCHGE CKYIEHLEAVTCKCQOEYFGERCCEK <u>(SEQ ID NO:26)</u>	84 a.a.	Human
Heparin-binding EGF-like growth factor	HB-EGF	DLQEADLLRLVTLSSKPQALATPNKEEH GKRKKKGKGLGKKRDPCLRKYKDFCIHGE CKYVKELRAPSCICHPGYHGERCHGLSL <u>(SEQ ID NO:27)</u>	86 a.a.	Human
Betacellulin	HBTC	DGNSTRSPETNGLLCGDPEENCAATTTQS KRKGHFSRCPKQYKHYCIKGRCRFVVAEQ TPSCVCDEGYIGARCERVDLFY <u>(SEQ ID NO:28)</u>	80 a.a.	Human
Betacellulin (C-terminal part)	HBTC	RKGHFSRCPKQYKHYCIKGRCRFVVAEQ TPSCVCDEGYIGARCERVDLFY <u>(SEQ ID NO:29)</u>	50 a.a.	Human

Please amend the fifth full paragraph on page 38, lines 19-23 of the specification with the following amended paragraph:

It is a further object of the present invention to provide a purified and isolated enhancer sequence having protein production increasing activity. Said purified and isolated enhancer sequence is preferably selected from the group comprising: YSFE (SEQ ID NO: 5), YSFED (SEQ ID NO: 30), YSFEDL (SEQ ID NO: 6), YSFEDLY (SEQ ID NO: 7), YSFEDLYR (SEQ ID NO: 8) and YSFEDLYRR (SEQ ID NO: 9), a fragment thereof, a molecular chimera thereof, and variants thereof.